Nkarta (NKTX) Other Operating Expenses (2019 - 2020)
Nkarta's (NKTX) quarterly Other Operating Expenses came in at -$40.7 million in Q2 2020, down 7148.62% quarter-over-quarter from $578000.0 in Q1 2020.
Nkarta (NKTX) Other Operating Expenses (2019 - 2020) Analysis & Trends
Nkarta's Other Operating Expenses history runs 2 years deep, the most recent figure standing at -$40.7 million for Q2 2020.
- On a quarterly basis, Other Operating Expenses changed N/A year-over-year to -$40.7 million in Q2 2020; TTM through Mar 2021 was -$40.7 million, a 2248.79% decrease from a year earlier, with the FY2020 full-year figure at -$40.2 million, down 3147.27% from the prior year.
- Other Operating Expenses declined to -$40.7 million in Q2 2020 per NKTX's latest filing, from $578000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $3.4 million in Q3 2019 and bottomed at -$40.7 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Nkarta | 170.79 Mn | 170.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -40.74 Mn |
| Mar 31, 2020 | 578,000.00 |
| Dec 31, 2019 | -2.07 Mn |
| Sep 30, 2019 | 3.38 Mn |